Clinical trial outcomes presented in Cremona, Italy
Rna Diagnostics (RnaDx) presented the findings of three clinical trials at the 5th International Symposium, Primary Systemic Treatment in the Management of Operable Breast Cancer in Cremona Italy. Dr. Ken Pritzker’s presentation, "RNA disruption as a measure of drug response in neoadjuvant therapy", was well received by the select audience of international experts. This conference drew together leaders in the field of primary breast cancer treatment with a particular focus on neoadjuvant therapy.
The audience reception was very encouraging. “People are looking for a reliable response marker,” Dr. Pritzker, CEO of Rna Diagnostics states. “RDA™ appears to be the leading assessment marker they are looking for.”
Part of the clinical work presented was performed in collaboration with the Azienda Istituti Ospitalieri di Cremona, Cremona, Italy. It showed that the RDA test can detect RNA disruption as early as 15 days from the start of chemotherapy. It also demonstrated that RDA was effective in three different classes of drugs. The paper will be published soon by Oxford University Press in the Journal of the National Cancer Institute (JNCI).
Opportunities for RDA™ in the UK and Germany
John Connolly, Rna Diagnostics’ VP Corporate Development, has initiated programs in the UK and Germany that will lead to engagement with the national healthcare systems of these key markets. John met with the National Institute for Health and Clinical Excellence (NICE) in Manchester, England. NICE advises the UK National Health Service on the adoption of new health technologies. NICE encouraged Rna Diagnostics to pursue its Medical Technologies Evaluation Programme, a programme that will lead to national adoption and reimbursement in the United Kingdom.
In Germany we have engaged in a programme to introduce RDA to the “Gemeinsamer Bundesausschuss” (G-BA), the body charged with clinical adoption and reimbursement and a programme to prepare for “selective contracting”, a requirement for initiating targeted sales in Germany.
Dr. Sanaa Noubir, Clinical Development Manager
We are pleased to announce that Dr. Sanaa Noubir has been hired as Clinical Development Manager for Rna Diagnostics. Dr. Noubir will assist in the development and management of collaborations with clinical partners and develop integrated programs to stimulate market awareness and early adopters for RDA.
“We’re delighted to have Dr. Noubir join us as she brings a wealth of experience and knowledge in cell biology plus recent training in business administration,” say Dr. Ken Pritzker, CEO of Rna Diagnostics. “We look forward to having her help advance RDA towards market by increasing our liaison with key opinion leaders and other interested parties.”
Dr. Noubir has a PhD in Genetics and Molecular Biology from the University of Paris Sud XI, Orsay, France. She has an MBA from the Schulich School of Business, York University.